These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20002308)

  • 1. Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C.
    Lim AK; Patel N; Eckersley RJ; Cobbold JF; Crossey MM; Cosgrove DO; Goldin RD; Thomas HC; Taylor-Robinson SD
    J Viral Hepat; 2010 Nov; 17(11):778-83. PubMed ID: 20002308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C.
    Lim AK; Taylor-Robinson SD; Patel N; Eckersley RJ; Goldin RD; Hamilton G; Foster GR; Thomas HC; Cosgrove DO; Blomley MJ
    Gut; 2005 Jan; 54(1):128-33. PubMed ID: 15591518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic vein transit time of SonoVue: a comparative study with Levovist.
    Lim AK; Patel N; Eckersley RJ; Goldin RD; Thomas HC; Cosgrove DO; Taylor-Robinson SD; Blomley MJ
    Radiology; 2006 Jul; 240(1):130-5. PubMed ID: 16720867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography.
    Li N; Ding H; Fan P; Lin X; Xu C; Wang W; Xu Z; Wang J
    Ultrasound Med Biol; 2010 Jul; 36(7):1066-75. PubMed ID: 20620694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease.
    Lim AK; Patel N; Eckersley RJ; Fitzpatrick J; Crossey MM; Hamilton G; Goldin RD; Thomas HC; Vennart W; Cosgrove DO; Taylor-Robinson SD
    J Viral Hepat; 2011 Oct; 18(10):e530-4. PubMed ID: 21914073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
    Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
    Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C.
    Borsoi Viana MS; Takei K; Collarile Yamaguti DC; Guz B; Strauss E
    Ann Hepatol; 2009; 8(1):26-31. PubMed ID: 19221530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
    Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
    Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic vein transit time of second-generation ultrasound contrast agent: new tool in the assessment of portal hypertension.
    Luisa S; Vitale G; Sorbo AR; Maurizio P; Lodovico RG
    J Ultrasound; 2017 Mar; 20(1):43-52. PubMed ID: 28298943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-invasive fibrosis assessment in chronic hepatitis C: aspartate-aminotransferase to platelet ratio index (APRI) and transient elastography (FibroScan)].
    Pár A; Pár G
    Orv Hetil; 2010 Nov; 151(47):1951-5. PubMed ID: 21071307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study.
    Blomley MJ; Lim AK; Harvey CJ; Patel N; Eckersley RJ; Basilico R; Heckemann R; Urbank A; Cosgrove DO; Taylor-Robinson SD
    Gut; 2003 Aug; 52(8):1188-93. PubMed ID: 12865280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Hepatic Transit Time (HTT) in Evaluation of Portal Vein Pressure in Gastroesophageal Varices Patients.
    Lin YQ; Jiang B; Li HQ; Jin CX; Wang H
    J Ultrasound Med; 2019 Sep; 38(9):2305-2314. PubMed ID: 30609088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
    Yu ML; Lin SM; Lee CM; Dai CY; Chang WY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Liaw YF
    Hepatology; 2006 Nov; 44(5):1086-97. PubMed ID: 17058238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
    Snyder N; Nguyen A; Gajula L; Soloway R; Xiao SY; Lau DT; Petersen J
    Clin Chim Acta; 2007 Jun; 381(2):119-23. PubMed ID: 17442291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
    Knop V; Hofmann WP; Buggisch P; Klinker H; Mauss S; Günther R; Hinrichsen H; Hüppe D; Pfeiffer-Vornkahl H; Simon KG; Berg T; Manns MP; Friedrich-Rust M;
    J Viral Hepat; 2019 Feb; 26(2):224-230. PubMed ID: 30315694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort.
    Holmberg SD; Lu M; Rupp LB; Lamerato LE; Moorman AC; Vijayadeva V; Boscarino JA; Henkle EM; Gordon SC;
    Clin Infect Dis; 2013 Jul; 57(2):240-6. PubMed ID: 23592832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.